Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Holding PCVX?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.1Last Year’s EPS
-1.83Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2020
|% Change Since: -18.34%
|Next Earnings Date:Aug 12, 2020
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in financial strength, clinical development, and regulatory interactions, particularly with VAX-24 and VAX-31. However, there are challenges related to achieving desired serotype coverage and uncertainties in Phase III progress and FDA approval. Overall, the company is well-positioned but faces some strategic decisions and regulatory hurdles.Company Guidance
During the Vaxcyte Q4 2023 earnings call, the executives provided detailed guidance on the advancement and potential of their pneumococcal conjugate vaccines (PCVs), VAX-24 and VAX-31. Key metrics included the announcement of the successful completion of the VAX-24 adult Phase II program, which demonstrated superior immune responses compared to Prevnar 20, and the initiation of the VAX-31 adult clinical program. The company outlined its strategy for Phase III trials, expecting to initiate the pivotal studies in 2024 and 2025, depending on whether VAX-24 or VAX-31 is advanced. Additionally, Vaxcyte highlighted their strong financial position, with over $2 billion in cash following recent financings, which will support the continued development and potential commercialization of their PCV programs. The company anticipates several key milestones, including the completion of the VAX-31 adult Phase I/II study by Q3 2024 and the VAX-24 infant Phase II study data in 2025. Vaxcyte also discussed their investments in manufacturing capacity to support global commercialization and their ongoing efforts in advancing earlier-stage vaccine candidates targeting Group A Strep and other diseases.Strong Financial Position
Vaxcyte raised approximately $545 million in net proceeds in a follow-on financing last April and added another $816 million earlier this month. Pro forma, after this most recent financing, the company had over $2 billion in cash and investments as of year-end.
Successful VAX-24 and VAX-31 Developments
Completion of VAX-24 adult Phase II program with positive results and initiation of VAX-31 adult clinical program. VAX-31 Phase I portion started in November and Phase II portion began in early January with completion of enrollment less than a month later.
Regulatory and Manufacturing Progress
Successful end of Phase II meeting with FDA for VAX-24 and encouraging feedback on CMC-related matters. Expanded relationship with Lonza and exercise of option on Sutro Biopharma for future manufacturing.
Broad Vaccine Coverage Potential
VAX-24 and VAX-31 designed to cover more serotypes than any current pneumococcal vaccine, with VAX-31 potentially covering approximately 95% of IPD circulating in the U.S. adult population.
Strong Pipeline and Investment in Manufacturing
Continued advancement of earlier-stage vaccine candidates and investment in a dedicated manufacturing suite at Lonza with a capital cost of approximately $300 million to $350 million.
---
PCVX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PCVX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $107.56 | $104.07 | -3.24% |
| Aug 06, 2024 | $73.93 | $70.52 | -4.61% |
| May 08, 2024 | $66.79 | $65.57 | -1.83% |
| Feb 27, 2024 | $81.05 | $75.11 | -7.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vaxcyte, Inc. (PCVX) report earnings?
Vaxcyte, Inc. (PCVX) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Vaxcyte, Inc. (PCVX) earnings time?
Vaxcyte, Inc. (PCVX) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCVX EPS forecast?
PCVX EPS forecast for the fiscal quarter 2024 (Q4) is -1.1.
---